NON SMALL CELL LUNG CARCINOMA NSCLC
Clinical trials for NON SMALL CELL LUNG CARCINOMA NSCLC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CARCINOMA NSCLC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CARCINOMA NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy showdown: new drug challenges chemo for lung cancer
Disease control OngoingThis study compared a new immunotherapy drug called durvalumab against standard chemotherapy as the first treatment for advanced non-small cell lung cancer. It involved 669 patients whose cancer had a specific biomarker (high PD-L1 expression) and had not received prior treatment…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Drug combo takes on standard chemo in major lung cancer trial
Disease control OngoingThis large, late-stage trial is comparing a new two-drug immunotherapy combination (durvalumab + tremelimumab) against standard chemotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination helps patients live longer. The study enrolled n…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New immune therapy battle against advanced lung cancer
Disease control OngoingThis large global study tested whether immunotherapy drugs (given alone or in combination) work better than standard chemotherapy as a first treatment for advanced non-small cell lung cancer. It involved over 1,100 patients whose cancer had spread and who had not received prior t…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC